PMPankaj Malhotra

Pankaj Malhotra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pankaj Malhotra has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction to: Genetic Spectrum in F13A1 Detected by Next-Generation Sequencing Among North Indian Patients with FXIII Deficiency

    by Ritika Sharma, Manu Jamwal, Namrata Singh, Prashant Sharma, Deepak Bansal, Amita Trehan, Pankaj Malhotra, Arihant Jain, Jasmina Ahluwalia, Reena Das, et al.

    [This corrects the article DOI: 10.1007/s12288-022-01579-1.].

  • Genetic Spectrum in F13A1 Detected by Next-Generation Sequencing Among North Indian Patients with FXIII Deficiency

    by Ritika Sharma, Manu Jamwal, Namrata Singh, Prashant Sharma, Deepak Bansal, Amita Trehan, Pankaj Malhotra, Arihant Jain, Jasmina Ahluwalia, Reena Das, et al.

    Purpose The study aimed to explore the molecular defects underlying FXIII deficiency. Materials and Methods Sixteen unrelated cases were enrolled based on the indication of the urea clot solubility test and Factor XIII-A antigen levels. Cases were further subjected to targeted next-generation sequencing (custom gene panel: F7, F8, VWF, F9, F13A1, F13B). The pathogenic/likely pathogenic variants were validated by Sanger sequencing in the patients and family members. Results Mean age of referral to our center was 27.2 years (8 week-67 years). Consanguinity was found in only one of the 16 cases and 9 cases presented in infancy. The most common symptoms were skin bleeds (69%) and umbilical cord bleed (50%). The clot solubility test was positive in 12, inconclusive in 1, and normal in 3. Mean FXIII-A levels were 15.7 IU/dL (range 0.6 to 49.5 IU/dL). Pathogenic/likely pathogenic variants in F13A1 were found in 11 (69%). Nine cases (82%) were homozygous, and two were compound heterozygous. Total eleven variants were found of which four were missense (c.1226G>A; c.998C>T; c.631G>C; c.2134A>C); three deletion (c.521delG; c.742delA; c.1405_1408delCAAA); two nonsense (c.1112G>A; c.1127G>A) and two splice site (c.1909-1G>C; c.2045G>A). No probably pathogenic variant was found in the F13B. Conclusion Inherited FXIII deficiency with bleeding is associated with genetic defects in predominantly the F13A1 gene. A variety of variants were seen in this cohort. A nonsense variant c.1127G>A found in three of our cases seems to be recurrent. This data will contribute to designing functional studies and antenatal testing in affected families.


  • Next-Generation Sequencing Based Approach to Identify Underlying Genetic Defects of Glanzmann Thrombasthenia

    by Ritika Sharma, Manu Jamwal, Hari Kishan Senee, Varun Uppal, Jasbir Kaur Hira, Parveen Bose, Narender Kumar, Deepak Bansal, Amita Trehan, Pankaj Malhotra, et al.

    Glanzmann thrombasthenia (GT) is an autosomal recessive platelet function disorder characterized by mucocutaneous bleeding as the most common clinical phenotype. Patients with GT have normal platelet counts, platelet morphology but reduced platelet aggregation in response to various agonists. Homozygosity or compound heterozygosity for variants in the ITGA2B/ITGB3 genes is the genetic basis for GT. Establishing a molecular diagnosis is definitive and is important for predictive testing. Using multi-gene panels is an accurate, faster, and cost-effective mode as compared to Sanger sequencing in large genes. We used a targeted resequencing based approach to identify pathogenic variants in eight cases in seven families. These variants were validated using Sanger sequencing in patients as well as family members and were predicted probably pathogenic using in-silico prediction tools. The variants include three missense (3/7 = 43%) (ITGA2B:c.1028 T > C, ITGA2B:c.1186G > A, ITGB3:c.1388G > C), two deletions (ITGA2B:c.559delG, ITGA2B:c.3092delT), one duplication (ITGA2B:c.1424_1427dupAGGT) and nonsense variant (ITGA2B:c.2578C > T, p.Gln860Ter). Except for one case which was compound heterozygous, the rest of the cases were homozygous. We found two novel variants that are reported for the first time in GT. The targeted resequencing based approach revealed varied genetic variants in North Indian patients, including two novels ones. The high yield of our panel indicates its suitability for usage in larger cohorts for the genetic diagnosis of GT patients. This approach is cost-effective and less cumbersome as compared to Sanger sequencing for these large size genes with multiple exons. The information so obtained is helpful in prenatal testing, carrier analysis, and genetic counseling.


  • Next-generation sequencing-based molecular diagnosis of chronic non-spherocytic hemolysis in erythrocytic enzymopathies

    by Manu Jamwal, Anu Aggarwal, Prashant Sharma, Deepak Bansal, Pankaj Malhotra, Arindam Maitra, Reena Das

  • First report of the mutational and phenotypic spectrum of Hereditary Spherocytosis in Indian patients by targeted resequencing

    by Anu Aggarwal, Manu Jamwal, Prashant Sharma, Man Updesh Singh Sachdeva, Pankaj Malhotra, Deepak Bansal, Reena Das

  • A homozygous KLF1 gene mutation presenting as mild Thalassemia Intermedia unraveled by targeted Next Generation Sequencing

    by Neetu Rani, Manu Jamwal, Jasbir Kaur, Pankaj Malhotra, Prashant Sharma, Arindam Maitra, Ranvir Singh, Subhash Varma, Reena Das

    The krupple-like factor 1 (KLF1) is a crucial transcription factor that is responsible for the proper maturation of the erythroid cells. Recent studies have demonstrated that mutations in KLF1 gene may lead to increased fetal hemoglobin (HbF) and reduced or borderline hemoglobin A2 (HbA2) levels. Increased HbF levels and concomitant α-thalassemia are two main modifiers that can ameliorate the clinical and hematological severity of β-thalassemia. Mutations in KLF1 have been found in association with β thalassemia. DNA was extracted with QIAmp DNA Blood kit and quantified spectrophotometrically. Gap PCR was used to screen common HPFH deletions and Sanger’s sequencing was done to screen β-globin (HBB) mutations. Libraries were prepared using TruSight One sequencing panel and sequenced on MiSeq Sequencing System. MiSeq Reporter and Variant Studio were used for data analysis. A 56 years male presented with splenomegaly and unconjugated hyperbilirubinemia with normal hematological indices. Hemoglobin high performance liquid chromatography revealed 72.3% HbF, 0.5% HbA2 and 25.2% HbA0. Patient was found to be clinically consistent with mild TI. No mutation/s in HBB was found by Sangers sequencing. Hereditary Persistence of Fetal Hemoglobin (HPFH) deletions [HPFH1, HPFH2, HPFH3, ChineseG deletion, Asian-Indian inversion-deletion] were also found to be negative. Targeted resequencing revealed a novel homozygous probably causative mutation in KLF1 [c. 943C>T (p.Arg301Cys)]. This mutation was found to be probably damaging via PolyPhen2 and SIFT. The patient's son showed 5% HbF with heterozygous mutation. This is the first report from India where a homozygous mutation in KLF1 gene is implicated with high HbF in a patient with TI. Thus, mutations which affect the activity of KLF1 gene may lead to high level of fetal hemoglobin in patients presenting as TI with no HBB mutations. The krupple-like factor 1 (KLF1) is a crucial transcription factor that is responsible for the proper maturation of the erythroid cells. Recent studies have demonstrated that mutations in KLF1 gene may lead to increased fetal hemoglobin (HbF) and reduced or borderline hemoglobin A2 (HbA2) levels. Increased HbF levels and concomitant α-thalassemia are two main modifiers that can ameliorate the clinical and hematological severity of β-thalassemia. Mutations in KLF1 have been found in association with β thalassemia. DNA was extracted with QIAmp DNA Blood kit and quantified spectrophotometrically. Gap PCR was used to screen common HPFH deletions and Sanger’s sequencing was done to screen β-globin (HBB) mutations. Libraries were prepared using TruSight One sequencing panel and sequenced on MiSeq Sequencing System. MiSeq Reporter and Variant Studio were used for data analysis. A 56 years male presented with splenomegaly and unconjugated hyperbilirubinemia with normal hematological indices. Hemoglobin high performance liquid chromatography revealed 72.3% HbF, 0.5% HbA2 and 25.2% HbA0. Patient was found to be clinically consistent with mild TI. No mutation/s in HBB was found by Sangers sequencing. Hereditary Persistence of Fetal Hemoglobin (HPFH) deletions [HPFH1, HPFH2, HPFH3, ChineseG deletion, Asian-Indian inversion-deletion] were also found to be negative. Targeted resequencing revealed a novel homozygous probably causative mutation in KLF1 [c. 943C>T (p.Arg301Cys)]. This mutation was found to be probably damaging via PolyPhen2 and SIFT. The patient's son showed 5% HbF with heterozygous mutation. This is the first report from India where a homozygous mutation in KLF1 gene is implicated with high HbF in a patient with TI. Thus, mutations which affect the activity of KLF1 gene may lead to high level of fetal hemoglobin in patients presenting as TI with no HBB mutations.


  • CML with pregnancy: real challenges in developing nations

    by Kamal Kant Sahu, Deba Prasad Dhibar, Subhash Varma, Pankaj Malhotra

    We read with great pleasure the recent article published by Law et al. [1] in your esteemed journal. We hereby share our experience of treatment-related challenges while managing chronic myelogenou...


  • Is 18F-FDG-PET/CT a good MRD marker in patients with multiple myeloma? Comparison and correlation with biochemical markers/flowcytometry.

    by Uday Yanamandra, B.R. Mittal, Man Upadesh, Arun Reddy, Praveen Sharma, Kanhaiya Agarwal, Alka Khadwal, Gaurav Prakash, Neelam Varma, Subhash Varma, et al.

    8029 Background: Multiple myeloma is a heterogenous disorder with varied responses to chemotherapy. The response criteria are defined based on biochemical assays, bone marrow (BM) examination, flowcytometry and molecular assays. Lately PET/CT is employed in MRD analysis. We aimed at studying the correlation of 18F-FDG-PET/CT with various biochemical markers, bone marrow plasma cells, and flowcytometry MRD analysis as a cross-sectional comparison at a given time point in patients post myeloma therapy. Methods: This is a single-center non-interventional study as part of PIPET-M trial. Patients of multiple myeloma underwent 18F-FDG-PET/CT, biochemical evaluation including (SPEP, UPEP, SIFE, SFLC, β2M, LDH) and BM examination (for plasma cells percentage and flowcytometry for MRD) as part of end of treatment analysis. Patients were included after induction chemotherapy, pre-autologous transplant (within 30 days) or post-transplant (Day 100) for analyzing efficacy of therapy. PET- positivity was based on the PIPET-M staging (A validated staging system developed by the authors). Results: A total of 72 patients were screened of which 52 patients underwent PET/CT, biochemical evaluation including (SPEP, UPEP, SIFE, SFLC, β2M and LDH) and bone marrow examination. Concurrent flowcytometry for MRD was done only in 11 patients. PET positivity had no relation with the pre transplant biochemical markers (SPEP, UPEP, SIFE) [χ2 - (1, 53)-0.34, p-0.56; (1, 52) - 2.18, p-0.14; (1, 52) – 0.32, p-0.57 respectively] or BM plasma cell percentage (p-0.64). In PET positive patients, β2M and LDH were higher (p - 0.032), whereas SFLC ratio though higher was not statistically significant (p-0.61). There was a good agreement between PET positivity and MRD by flowcytomtery (Cohen’s κ - 0.662, p < 0.001). Conclusions: 18F-FDG-PET/CT is a good marker for MRD analysis with good agreement with flowcytometry and disease activity markers such as β2M/ LDH. Its poor correlation with SPEP, UPEP, SIFE and BM plasma cell percentage can be secondary to undetectable levels of these markers in many patients (~ 84%) after therapy. A comparison of these markers for prognosticating PFS/OS is further warranted. Clinical trial information: U1111-1177-8850, REF/2015/12/010356.

  • Molecular response assessment at 3 months time point is better in late chronic phase chronic myeloid leukemia patients

    by Pankaj Malhotra, Santosh Chikkodi, Shano Naseem, Alka Khadwal, Gaurav Prakash, Kamal Kant Sahu, Neelam Varma, Subhash Varma, Savita Kumari, Vikas Suri

  • Effect of steroids on the activation status of platelets in patients with Immune thrombocytopenia (ITP)

    by Preeti Bhoria, Saniya Sharma, Neelam Varma, Pankaj Malhotra, Subhash Varma, Manni Luthra-Guptasarma

    The activation status of platelets in Immune Thrombocytopenia (ITP) patients--which is still somewhat controversial--is of potential interest, because activated platelets tend to aggregate (leading to excessive clotting or thromboembolic events) but cannot do so when platelet numbers are low, as in ITP. Although corticosteroids are the first line of therapy in ITP, the effect of steroids on activation of platelets has not been evaluated so far. We examined the status of platelet activation (with and without stimulation with ADP) in ITP patients, at the start of therapy (pre-steroid treatment, naive) and post-steroid treatment (classified on the basis of steroid responsiveness). We used flow cytometry to evaluate the levels of expression of P-selectin, and PAC-1 binding to platelets of 55 ITP patients and a similar number of healthy controls, treated with and without ADP. We found that platelets in ITP patients exist in an activated state. In patients who are responsive to steroids, the treatment reverses this situation. Also, the fold activation of platelets upon treatment with ADP is more in healthy controls than in ITP patients; treatment with steroids causes platelets in steroid-responsive patients to become more responsive to ADP-activation, similar to healthy controls. Thus steroids may cause changes in the ability of platelets to get activated with an agonist like ADP. Our results provide new insights into how, and why, steroid therapy helps in the treatment of ITP.